France A roundup of the top stories coming out of France’s pharma industry, including Sanofi’s consumer health unit spinout and EUR 40 million investment in antibody bioproduction; the French govenment’s unprecedented deal with Upsa; the Health Minister’s plans to lower the national social security system’s reimbursement of drugs; Servier’s newfound willingness…
France Pascal Brière, president of Biogaran, the leading French domestic player in generics, reflects on the development of the generic market since the 1999 Generic Substitution Act. Brière goes on to comment on Biogaran’s unique strategy of leveraging added solutions, international expansion, and biosimilars. He concludes with his thoughts on the…
Biogaran Biogaran was an initiative from Servier in the mid 1990s before there was even a generic pharmaceutical market in France. Could you speak of your history and of the origins of Biogaran and the vision behind starting this company? Biogaran is in line with my previous experience as I was…
See our Cookie Privacy Policy Here
